

the biology of
CANCER

THIRD EDITION

Robert A. Weinberg,
Massachusetts Institute
of Technology

With chapters by:

Richard Goldsby, Amherst College

Michael Hemann, Massachusetts Institute of Technology

Tyler Jacks, Massachusetts Institute of Technology



W. W. NORTON & COMPANY

Celebrating a Century of Independent Publishing

Detailed Contents

Chapter 1: The Biology and Genetics of Cells and Organisms	1	3.6	Tumor virus genomes persist in virus-transformed cells by becoming part of host-cell DNA	79
1.1 Mendel establishes the basic rules of genetics	2	3.7	Retroviral genomes become integrated into the chromosomes of infected cells	82
1.2 Mendelian genetics helps to explain Darwinian evolution	4	3.8	A version of the <i>src</i> gene carried by RSV is also present in uninfected cells	84
1.3 Mendelian genetics governs how both genes and chromosomes behave	6	3.9	RSV exploits a kidnapped cellular gene to transform cells	86
1.4 Chromosomes are altered in most types of cancer cells	9	3.10	The vertebrate genome carries a large group of proto-oncogenes	88
1.5 Mutations causing cancer occur in both the germ line and the soma	9	3.11	Slowly transforming retroviruses activate proto-oncogenes by inserting their genomes adjacent to these cellular genes	89
1.6 Genotype embodied in DNA sequences creates phenotype through proteins	12	3.12	Some retroviruses naturally carry oncogenes	92
1.7 Gene expression patterns also control phenotype	17	3.13	Bacterial cancers	94
1.8 Modification of chromatin proteins and DNA controls gene expression	20	3.14	Synopsis and prospects	95
1.9 Unconventional RNA molecules also affect the expression of genes	24	Key concepts		97
1.10 Metazoa are formed from components conserved over vast evolutionary time periods	26	Thought questions		98
1.11 Gene cloning techniques revolutionized the study of normal and malignant cells	27	Additional reading		99
Additional reading	29	Chapter 4: Cellular Oncogenes		101
Chapter 2: The Nature of Cancer	31	4.1	Transfection of DNA provides a strategy for detecting nonviral oncogenes	102
2.1 Tumors arise from normal tissues	32	4.2	Oncogenes discovered in human tumor cell lines are related to those carried by transforming retroviruses	104
2.2 Tumors arise from many specialized cell types throughout the body	34	4.3	Proto-oncogenes can be activated by genetic changes affecting either protein expression level or structure	107
2.3 Some types of tumors do not fit into the major classifications	42	4.4	Variations on a theme: the <i>myc</i> oncogene can arise via at least three additional distinct mechanisms	111
2.4 Cancers seem to develop progressively	44	4.5	A diverse array of structural changes in proteins can also lead to oncogene activation	117
2.5 Tumors are monoclonal growths	49	4.6	Synopsis and prospects	120
2.6 Cancers occur with vastly different frequencies in different human populations	51	Key concepts		122
2.7 The risks of cancers often seem to be increased by assignable influences, including lifestyle	54	Thought questions		123
2.8 Specific chemical agents can induce cancer	56	Additional reading		123
2.9 Both physical and chemical carcinogens act as mutagens	57	Chapter 5: Growth Factors, Receptors, and Cancer		125
2.10 Mutagens may be responsible for some human cancers	60	5.1	Normal metazoan cells control each other's lives	126
2.11 Synopsis and prospects	61	5.2	The <i>Src</i> protein functions as a tyrosine kinase	129
Key concepts	63	5.3	The EGF receptor functions as a tyrosine kinase	132
Thought questions	64	5.4	An altered growth factor receptor can function as an oncoprotein	135
Additional reading	65	5.5	A growth factor gene can become an oncogene: the case of <i>sis</i>	138
Chapter 3: Cancer as an Infectious Disease	67	5.6	Transphosphorylation underlies the operations of many receptor tyrosine kinases	141
3.1 Peyton Rous discovers a chicken sarcoma virus	68	5.7	Yet other types of receptors enable mammalian cells to communicate with their environment	147
3.2 Rous sarcoma virus is discovered to transform infected cells in culture	69	5.8	Nuclear receptors sense the presence of low-molecular-weight lipophilic ligands	153
3.3 The continued presence of RSV is needed to maintain transformation	72	5.9	Integrin receptors sense association between the cell and the extracellular matrix	154
3.4 Viruses containing DNA molecules are also able to induce cancer	74			
3.5 Tumor viruses induce multiple changes in cell phenotype including acquisition of tumorigenicity	77			

5.10	The Ras protein, an apparent component of the downstream signaling cascade, functions as a G-protein	159	7.8	TSGs and their encoded proteins function in diverse ways	253
5.11	Synopsis and prospects	162	7.9	The NF1 protein acts as a negative regulator of Ras signaling	254
	Key concepts	167	7.10	APC facilitates egress of cells from colonic crypts	259
	Thought questions	169	7.11	KEAP1 regulates cellular response to oxidative stress	265
	Additional reading	169	7.12	Not all familial cancers can be explained by inheritance of mutant TSGs	268
Chapter 6: Cytoplasmic Signaling Circuitry Programs Many of the Traits of Cancer			171	7.13	Synopsis and prospects
6.1	A signaling pathway reaches from the cell surface into the nucleus	172		Key concepts	272
6.2	The Ras protein stands in the middle of a complex signaling cascade	176		Thought questions	273
6.3	Tyrosine phosphorylation controls the location and thereby the actions of many cytoplasmic signaling proteins	177		Additional reading	273
6.4	SH2 and SH3 groups explain how growth factor receptors activate Ras and acquire signaling specificity	182	Chapter 8: pRb and Control of the Cell Cycle Clock		
6.5	Ras-regulated signaling pathways: A cascade of kinases forms one of three important signaling pathways downstream of Ras	184	8.1	Cell growth and division is coordinated by a complex array of regulators	276
6.6	Ras-regulated signaling pathways: a second downstream pathway controls inositol lipids and the Akt/PKB kinase	189	8.2	Cells make decisions about growth and quiescence during a specific period in the G ₁ phase	280
6.7	Ras-regulated signaling pathways: a third downstream pathway acts through Ral, a distant cousin of Ras	198	8.3	Cyclins and cyclin-dependent kinases constitute the core components of the cell cycle clock	282
6.8	The JAK-STAT pathway allows signals to be transmitted from the plasma membrane directly to the nucleus	200	8.4	Cyclin-CDK complexes are also regulated by CDK inhibitors	287
6.9	Cell adhesion receptors emit signals that converge with those released by growth factor receptors	202	8.5	Viral oncoproteins reveal how pRb blocks advance through the cell cycle	292
6.10	The canonical and non-canonical Wnt pathways control diverse cellular phenotypes	204	8.6	pRb is deployed by the cell cycle clock to serve as a guardian of the restriction-point gate	295
6.11	G-protein-coupled receptors can also drive normal and neoplastic proliferation	208	8.7	E2F transcription factors enable pRb to implement growth-versus-quiescence decisions	297
6.12	Four additional “dual-address” signaling pathways contribute in various ways to normal and neoplastic proliferation	211	8.8	A variety of mitogenic signaling pathways control the phosphorylation state of pRb	301
6.13	The Hippo signaling circuit integrates diverse inputs to govern diverse cell phenotypes	217	8.9	The Myc protein governs decisions to proliferate or differentiate	302
6.14	Well-designed signaling circuits require both negative and positive feedback controls	218	8.10	TGF- β prevents phosphorylation of pRb and thereby blocks cell cycle progression	307
6.15	Synopsis and prospects	221	8.11	pRb function and the controls of differentiation are closely linked	309
	Key concepts	229	8.12	Control of pRb function is perturbed in most if not all human cancers	311
	Thought questions	230	8.13	Synopsis and prospects	315
	Additional reading	231		Key concepts	318
Chapter 7: Tumor Suppressor Genes			233		320
7.1	Cell fusion experiments indicate that the cancer phenotype is recessive	234		Thought questions	320
7.2	The recessive nature of the cancer cell phenotype requires a genetic explanation	235		Additional reading	320
7.3	The retinoblastoma tumor provides a solution to the genetic puzzle of TSGs	236	Chapter 9: p53: Master Guardian and Executioner		
7.4	Incipient cancer cells eliminate wild-type copies of TSGs by a variety of mechanisms	240	9.1	DNA tumor viruses lead to the discovery of p53	324
7.5	The Rb gene often undergoes loss of heterozygosity in tumors	242	9.2	<i>p53</i> is discovered to be a tumor suppressor gene	324
7.6	Loss-of-heterozygosity events can be used to find TSGs	244	9.3	Inherited mutations affecting <i>p53</i> predispose individuals to a variety of tumors	327
7.7	Promoter methylation represents an important mechanism for inactivating TSGs	247	9.4	Mutant versions of p53 interfere with normal p53 function	327
			9.5	p53 protein molecules usually have short lifetimes	330
			9.6	Various signals cause p53 induction	332
			9.7	DNA damage and deregulated growth signals cause p53 stabilization	333
			9.8	Mdm2 destroys its own creator	335
			9.9	ARF and p53-mediated apoptosis protect against cancer by monitoring intracellular signaling	340
			9.10	p53 functions as a transcription factor that halts cell cycle advance in response to DNA damage and attempts to aid in the repair process	341
			9.11	Prolonged DNA damage and oncogene activation can induce p53-dependent senescence	345
			9.12	The apoptosis program participates in normal tissue development and maintenance	348

9.13	Apoptosis is a complex biochemical program that often depends on mitochondria	349	11.9	Human cells are constructed to be highly resistant to immortalization and transformation	448
9.14	Both intrinsic and extrinsic apoptotic programs can lead to cell death	359	11.10	Mammalian evolution contributed to the complexity of human cell transformation	451
9.15	Cancer cells deploy numerous ways to inactivate their apoptotic machinery	363	11.11	Nonmutagenic agents, including those favoring cell proliferation, make important contributions to tumorigenesis	453
9.16	p53 inactivation provides an advantage to incipient cancer cells at a number of steps in tumor progression	366	11.12	Mitogenic agents, key governors of human cancer incidence, can act as human tumor promoters	458
9.17	Additional forms of cell death may limit the survival of cancer cells	367	11.13	Chronic inflammation often serves to promote tumor progression in mice and humans	460
9.18	Synopsis and prospects	370	11.14	Inflammation-dependent tumor promotion operates through defined signaling pathways	462
Key concepts		372	11.15	Metabolism is the elusive heart of the cancer process	465
Thought questions		373	11.16	Synopsis and prospects	470
Additional reading		373	Key concepts		475
Chapter 10: Eternal Life: Cell Immortalization and Tumorigenesis		375	Thought questions		476
			Additional reading		476
10.1	Normal cell populations appear to register the number of cell generations separating them from their ancestors in the early embryo	376	Chapter 12: Shaping and Characterizing the Cancer Genome		479
10.2	Cells need to become immortalized in order to form a cell line	378	12.1	Tissues are organized to minimize the progressive accumulation of mutations	480
10.3	Cancer cells need to become immortal in order to form tumors	380	12.2	The properties of stem cells make them good candidates to be cells-of-origin of cancer	483
10.4	The proliferation of cultured cells is also limited by the telomeres of their chromosomes	384	12.3	Apoptosis, drug pumps, and DNA replication quality control mechanisms offer tissues a way to minimize the accumulation of mutant preneoplastic cells	485
10.5	Telomeres are complex molecular structures that are not easily replicated	389	12.4	Cell genomes are under constant attack from endogenous biochemical processes	491
10.6	Incipient cancer cells can escape crisis by expressing telomerase	391	12.5	Cell genomes are under occasional attack from exogenous mutagens and their metabolites	494
10.7	Telomerase plays a key role in the proliferation of human cancer cells	396	12.6	Cells deploy a variety of defenses to protect DNA molecules from attack by mutagens	501
10.8	Some immortalized cells can maintain telomeres without telomerase	399	12.7	Repair enzymes fix DNA that has been altered by mutagens	502
10.9	Telomeres play different roles in the cells of laboratory mice and in human cells	401	12.8	Inherited defects in nucleotide-excision repair, base-excision repair, and mismatch repair lead to specific cancer susceptibility syndromes	508
10.10	Telomerase-negative mice show both decreased and increased cancer susceptibility	403	12.9	A variety of other DNA repair defects confer increased cancer susceptibility	514
10.11	The mechanisms underlying cancer pathogenesis in telomerase-negative mice may also operate during the development of human tumors	406	12.10	The karyotype of cancer cells is often changed through alterations in chromosome structure	520
10.12	Synopsis and prospects	409	12.11	The karyotype of cancer cells is often changed through alterations in chromosome number	524
Key concepts		412	12.12	Advances in genome sequencing technologies have fueled a revolution in cancer genomics	528
Thought questions		413	12.13	Genomic analysis reveals that human cancers differ with respect to mutational burden, patterns of mutations, and copy number gains and losses	529
Additional reading		413	12.14	Cancer genomes contain driver and passenger gene mutations	534
Chapter 11: Multi-Step Tumorigenesis		415	12.15	Cancer genomic studies reveal both inter-tumoral and intra-tumoral heterogeneity	535
11.1	Most human cancers develop over many decades of time	416	12.16	Synopsis and prospects	539
11.2	Histopathology provides evidence of multi-step tumor formation	419	Key concepts		546
11.3	Cells accumulate genetic and epigenetic alterations as tumor progression proceeds	424	Thought questions		547
11.4	Cancer development seems to follow the rules of Darwinian evolution	429	Additional reading		547
11.5	Multi-step tumor progression helps to explain familial polyposis and field cancerization	431	Chapter 13: Dialogue Replaces Monologue: Heterotypic Interactions and the Biology of Angiogenesis		549
11.6	Intra-tumor diversification can outrun Darwinian selection	432	13.1	Normal and neoplastic epithelial tissues are formed from interdependent cell types	551
11.7	Tumor stem cells further complicate the Darwinian model of clonal succession and tumor progression	437	13.2	The extracellular matrix represents a critical component of the tumor microenvironment	561
11.8	Multiple lines of evidence reveal that normal cells are resistant to transformation by a single mutated gene	443			

13.3	Tumors resemble wounded tissues that do not heal	563	15.5	MHC molecules play key roles in antigen recognition by T cells	710
13.4	Experiments directly demonstrate that stromal cells are active contributors to tumorigenesis	575	15.6	T cells that recognize MHC-I have different roles from those that recognize MHC-II	714
13.5	Macrophages and myeloid cells play important roles in activating the tumor-associated stroma	576	15.7	Dendritic cell activation of naive T cells is a key step in the generation of functional helper and cytotoxic T cells	714
13.6	Endothelial cells and the vessels that they form ensure tumors adequate access to the circulation	582	15.8	Tumor antigens are targets of the immune response to cancer	717
13.7	Tripping the angiogenic switch is essential for tumor expansion	588	15.9	Natural killer cells contribute to anti-cancer immunity	721
13.8	The angiogenic switch initiates a highly complex process	592	15.10	Macrophages make multiple contributions to tumor development	722
13.9	Anti-angiogenesis therapies have been employed to treat cancer	594	15.11	Regulatory T cells are indispensable negative regulators of the immune response that are co-opted by tumors to counteract immune attack	725
13.10	Nervous tissue contributes to tumor growth	599	15.12	Immune checkpoints act to limit immune responses	727
13.11	Synopsis and prospects	601	15.13	Synopsis and prospects	730
Key concepts		606	Key concepts		734
Thought questions		607	Thought questions		736
Additional reading		607	Additional reading		736
Chapter 14: Moving Out: Invasion and Metastasis		609	Chapter 16: Cancer Immunotherapy		737
14.1	The invasion–metastasis cascade begins with local invasiveness	612	16.1	Vaccination can prevent cancer caused by infectious agents	738
14.2	Epithelial–mesenchymal transitions profoundly reshape the phenotypes of carcinoma cells	615	16.2	Vaccination against human papillomaviruses prevents cervical cancer	740
14.3	Epithelial–mesenchymal transitions are often induced by contextual signals	622	16.3	Therapeutic vaccination is a potential treatment for cancer	742
14.4	EMTs are programmed by transcription factors that orchestrate key steps of embryogenesis	633	16.4	Passive immunization with antibodies can be used to treat cancer	745
14.5	Signals released by an array of stromal cell types contribute to the induction of invasiveness and intravasation	637	16.5	Lymphoma and breast cancer can be treated with monoclonal antibodies	748
14.6	EMT-inducing transcription factors may enable entrance into the stem cell state	643	16.6	Antibody–drug conjugates deliver toxic drugs to cells displaying tumor antigens	750
14.7	EMT-inducing transcription factors help drive malignant progression including metastatic dissemination	646	16.7	Cancer can be treated by adoptive cell transfer	754
14.8	The invasiveness of carcinoma cells depends on clearance of obstructing ECM	651	16.8	CART cells have predetermined specificity and bypass MHC-dependent antigen presentation	757
14.9	Motility enables cancer cells to move into space excavated by MMPs	656	16.9	Checkpoint inhibition is a distinct type of immunotherapy that modifies the behavior of immune cells	761
14.10	Intravasation and the formation of circulating tumor cells: first steps in perilous journeys	657	16.10	Checkpoint immunotherapies based on mouse studies have been applied in the oncology clinic	767
14.11	Colonization represents the most complex and challenging step of the invasion–metastasis cascade	667	16.11	Resistance to immune checkpoint inhibitors commonly arises	768
14.12	Successful metastatic colonization often involves complex adaptations	677	16.12	Lethal encounters between T cells and cancer cells can be encouraged by constructing bi-specific antibodies	769
14.13	An example of extreme metastatic specialization: metastasis to bone requires the subversion of osteoblasts and osteoclasts	679	16.13	T-cell–dependent immunotherapies can be hampered by T-cell exhaustion	771
14.14	Occult micrometastases threaten the long-term survival of many cancer patients	685	16.14	Synopsis and Prospects	773
14.15	Synopsis and prospects	686	Key Concepts		777
Key concepts		692	Thought questions		778
Thought questions		693	Additional reading		778
Additional reading		694	Chapter 17: The Rational Treatment of Cancer		781
Chapter 15: Crowd Control: Tumor Immunology		697	17.1	The development and clinical use of effective therapies will depend on accurate diagnosis of disease	784
15.1	The immune system continuously conducts surveillance of tissues	698	17.2	Surgery, radiotherapy, and chemotherapy are the major pillars on which current cancer therapies rest	792
15.2	The human immune system plays a critical role in warding off various types of human cancer	700	17.3	The present and future use of chemotherapy requires improved understanding of how anti-cancer drugs work	796
15.3	The immune system functions to destroy foreign invaders and abnormal cells in the body's tissues	704	17.4	Differentiation, synthetic lethality, and cell cycle checkpoints can be exploited to kill cancer cells	801
15.4	The diversity of B cell and T cell receptors arises from the stochastic diversification of the genes that encode them	708			

17.5	Functional and biochemical considerations dictate that only a subset of the defective proteins in cancer cells are attractive targets for drug development	803	17.14	EGF receptor antagonists may be useful for treating a wide variety of tumor types	841
17.6	Pharmaceutical chemists can generate and explore the biochemical properties of a wide array of potential drugs	811	17.15	Proteasome inhibitors yield unexpected therapeutic benefit	847
17.7	Drug candidates and their targets must be examined in cell models as an initial measurement of their utility in whole organisms	815	17.16	B-Raf discoveries have led to inroads into the melanoma problem	852
17.8	Studies of a drug's action in laboratory animals are an essential part of pre-clinical testing	819	17.17	Synopsis and prospects: challenges and opportunities on the road ahead	855
17.9	Promising candidate drugs are subjected to rigorous clinical tests in Phase I trials in humans	821		Key concepts	863
17.10	Phase II and III trials provide credible indications of clinical efficacy	824		Thought questions	864
17.11	Tumors often develop resistance to initially effective therapy	826		Additional reading	864
17.12	Targeting Bcl-2 to induce cell death	827		Abbreviations	A:1
17.13	Gleevec paved the way for the development of many other highly targeted compounds	830		Glossary	G:1
				Index	I:1